CINECA IRIS Institutional Research Information System

LOLLI, Marco Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.538
AS - Asia 6.998
EU - Europa 6.808
SA - Sud America 894
AF - Africa 220
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 10
Totale 25.503
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.199
SG - Singapore 2.805
IT - Italia 2.567
CN - Cina 1.643
DE - Germania 822
VN - Vietnam 723
BR - Brasile 654
IE - Irlanda 554
FR - Francia 510
SE - Svezia 475
GB - Regno Unito 414
IN - India 382
FI - Finlandia 310
KR - Corea 283
HK - Hong Kong 269
JP - Giappone 256
CA - Canada 238
UA - Ucraina 222
AT - Austria 197
NL - Olanda 189
ID - Indonesia 114
PL - Polonia 103
BD - Bangladesh 94
AR - Argentina 86
DK - Danimarca 65
MX - Messico 58
BE - Belgio 55
IQ - Iraq 50
PK - Pakistan 49
RU - Federazione Russa 46
ES - Italia 44
TW - Taiwan 44
TR - Turchia 42
CM - Camerun 41
IR - Iran 38
ZA - Sudafrica 36
CO - Colombia 35
RO - Romania 34
AU - Australia 32
CL - Cile 31
EC - Ecuador 31
CH - Svizzera 29
SN - Senegal 28
CZ - Repubblica Ceca 27
MY - Malesia 26
PT - Portogallo 25
NG - Nigeria 24
MA - Marocco 22
PH - Filippine 22
SA - Arabia Saudita 22
UZ - Uzbekistan 22
VE - Venezuela 21
GR - Grecia 18
EG - Egitto 17
JO - Giordania 17
TH - Thailandia 16
AE - Emirati Arabi Uniti 14
HR - Croazia 12
PY - Paraguay 11
BG - Bulgaria 10
NO - Norvegia 10
SI - Slovenia 10
LT - Lituania 9
RS - Serbia 9
TN - Tunisia 9
UY - Uruguay 9
DZ - Algeria 8
EE - Estonia 8
EU - Europa 8
GE - Georgia 8
IL - Israele 8
KE - Kenya 8
NP - Nepal 8
BO - Bolivia 7
HU - Ungheria 7
PE - Perù 7
AL - Albania 6
CI - Costa d'Avorio 6
HN - Honduras 6
OM - Oman 6
SK - Slovacchia (Repubblica Slovacca) 6
BZ - Belize 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
JM - Giamaica 5
LB - Libano 5
MO - Macao, regione amministrativa speciale della Cina 5
AZ - Azerbaigian 4
CY - Cipro 4
ET - Etiopia 4
KZ - Kazakistan 4
PA - Panama 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
GH - Ghana 3
LU - Lussemburgo 3
LY - Libia 3
MT - Malta 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
Totale 25.461
Salva come PNG Salva come JPEG
Città #
Singapore 1.574
San Jose 1.282
Ashburn 860
Chandler 830
Santa Clara 677
Beijing 581
Dublin 546
Turin 388
Torino 358
Ann Arbor 328
Fairfield 289
Los Angeles 289
Houston 252
Frankfurt am Main 241
Nyköping 225
Jacksonville 207
Woodbridge 207
Ho Chi Minh City 206
Tokyo 191
Hefei 189
Seoul 183
Hong Kong 177
Munich 174
Vienna 174
The Dalles 172
Columbus 170
Lauterbourg 157
Wilmington 152
Seattle 149
Medford 141
Milan 139
Hanoi 130
Princeton 128
Dong Ket 124
Villeurbanne 121
Dearborn 119
Dallas 116
Buffalo 111
New York 110
Cambridge 109
Redwood City 108
Council Bluffs 106
Rome 99
Helsinki 98
Pisa 85
Jakarta 82
Fremont 78
Warsaw 72
Turku 70
Bengaluru 68
Boardman 62
Boston 61
Ottawa 60
Guangzhou 57
São Paulo 57
Redondo Beach 50
Toronto 50
Shanghai 49
Orem 48
Copenhagen 46
Nanjing 46
Nuremberg 46
Brussels 41
Douala 39
Hangzhou 38
London 36
Mumbai 36
Chicago 34
Düsseldorf 34
Haiphong 34
Amsterdam 33
Chennai 32
Washington 32
Naples 29
Mexico City 28
Montreal 28
Paris 27
Brooklyn 26
Da Nang 26
Horia 26
Lappeenranta 26
Delhi 25
San Diego 24
Stockholm 24
Norwalk 21
Phoenix 21
Québec 21
Atlanta 20
Baghdad 19
Bologna 19
San Francisco 19
Tianjin 19
Pune 18
Taipei 18
Chengdu 17
Santiago 17
Abuja 16
Belo Horizonte 16
Manchester 16
Rivoli 16
Totale 15.045
Salva come PNG Salva come JPEG
Nome #
Nuovi inibitori della diidroorotato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide 797
1,2,5-Oxadiazole analogues of leflunomide and related compounds 527
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 498
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION 452
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 426
New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold 319
4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues 306
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 297
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 290
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a bioisosteric scaffold hopping approach to flufenamic acid 280
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 266
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 258
Multiple catalytic activities of human 17β-hydroxysteroid dehydrogenase type 7 respond differently to inhibitors. 255
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 253
Design, synthesis, and biological evaluation of flufenamic acid derived bioisosteres as inhibitors of aldo-keto reductase 1C3 (AKR1C3) expressed in prostate cancer 239
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 236
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 232
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 232
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 231
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 230
Recent advances in the synthesis of analogues of phytohormones strigolactones with ring-closing metathesis as a key step 230
A novel SWCNT platform bearing DOTA and b-cyclodextrin units. "One shot" multidecoration under microwave irradiation. 221
NEW HYDROXYAZOLES INHIBITORS OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) OBTAINED BY SCAFFOLD HOPPING FROM FLUFENAMIC ACID AND INDOMETHACIN FOR CASTRATE RESISTANT PROSTATE CANCER 218
Design and synthesis of a library of pyrazolo[1,5-a]pyridine fluorophores for developing new fluorescent probes 212
Structure Activity Relationship of strigolactones via a novel, quantitative in planta bioassay 211
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 207
The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors 206
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 206
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 203
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 193
4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric γ-aminobutyric acid receptor binding site 193
Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans 189
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 189
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) 187
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 187
PROBING THE BICYCLIC HYDROXYPYRAZOLO[1,5-a]PYRIDINE SCAFFOLD AS A CARBOXYLIC ACID BIOISOSTERE IN THE GABAa RECEPTOR SYSTEM 182
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 181
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 181
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity 181
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 180
A new class of ibuprofen derivatives with reduced gastrotoxicity 176
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 175
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 170
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 170
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 166
Application of the arachno™ technology inside Educational fields: the introduction of parallel synthesis concepts inside an undergraduated lab 163
Targeting Castration Resistant Prostate Cancer (CRPC) by innovative AKR1C3 inhibitors based on the 3-hydroxybenzoisoxazole structure 163
Inibitori della diidroorotato deidrogenasi umana (hDHODH) per l'uso come antivirali 163
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 161
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells 160
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 160
Discovery and optimization of new OvCHT1 inhibitors based on the 4-hydroxy-1H-1,2,3-triazole ring 160
1H-pyrazole-4-carboxylic acids active against Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): discovery of a new scaffold for development of antimalarial agents 157
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 157
Five-Membered N-Heterocyclic Scaffolds as Novel Amino Bioisosteres at γ-Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters 156
Development of new hydroxypyrazole-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) 154
SAR STUDIES ON H2 ANTAGONISTS CONTAINING ALKYLAMINO SUBSTITUTED 1,2,5-THIADIAZOLE 1-OXIDE MOIETIES 152
Discovery of new NIK inhibitors by Structure-Based Drug Design 151
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 151
APPLICATION OF THE ARACHNO™ TECHNOLOGY FOR THE PARALLEL SYNTHESIS OF A LIBRARY OF ASPIRIN ANALOGUES 148
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 148
Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on gamma-aminobutyric acid (GABA) related compounds 146
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 145
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 144
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 142
ONE -POT ALKOXYMERCURATION-BROMODEMERCURIATION: A VERSATILE ACCESS TO 3-ALKOXY-2-BROMOPROPANOIC ESTERS 142
Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication 141
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 141
Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin 139
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 139
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 138
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 137
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats 135
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 132
Synthesis of new Gadolinium complexes for magnetic resonance imaging with improved relaxivity 130
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 130
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 128
Probing the bicyclic hydroxypyrazolo[1,5-a]pyridine scaffold as a carboxylic acid bioisostere in theGABAA receptor system 125
Synthesis and Structural Characterization of Regio Substituted 4-Hydroxy-1H-1,2,3-triazols as Possible Tool in Bioisosteric Applications 125
Synthesis of new gadolinium complexes for magnetic resonance imaging with improved relaxivity 125
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 125
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 124
4-Hydroxy-1H-1,2,3-Triazol-5-yl moiety as bioisoster of carboxylic group. Synthesis and pharmacological ionotropic glutamate receptors characterization of Glu analogues 121
The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses [Calistri A.*, Luganini A.*, co-first author] 121
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 121
Effects of new hydroxyazoles inhibitors of AKR1C3 on vitality of prostate and colorectal cancer cell lines 120
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 119
Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) 117
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 117
Improving the fluorescent profile of pyrazolo [1,5-a]pyridine fluorophores for developing new fluorescent probes 116
The (bio)chemical beaUty: La bellezza del faRmaCo attraverso la ReAltà Virtuale (URCA!) 114
Indomethacin Inhibits Proliferation In Cells Harbouring PIK3CA Mutations 114
Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin 113
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 112
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 111
Synthesis of new Plasmodium Falciparum dihydroorotate dehydrogenase inhibitors through the application of an isosteric portfolio 111
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 111
Hydroxypyrazolo[1,5-a]pyridine as a fluorescent carboxylic acid isostere: introducing GABAA receptor system affinities in the scaffold 109
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 109
Exploring Novel Compounds Targeting Mycobacterium tuberculosis Dihydroorotate Dehydrogenase: SAR Analysis and Biological Activity 108
Totale 18.839
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.808
article - articoli 0
book - libri 0
conference - conferenze 40.347
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.155
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021226 0 0 0 0 0 0 0 0 0 0 0 226
2021/20221.827 76 60 115 171 86 70 104 87 39 215 472 332
2022/20233.022 290 332 109 294 217 680 262 200 254 90 169 125
2023/20241.751 207 215 114 88 121 189 190 80 25 159 138 225
2024/20254.849 116 302 310 499 828 354 179 225 698 238 390 710
2025/20269.035 1.038 541 541 1.013 925 411 1.456 378 864 1.230 488 150
Totale 26.044